Glucocorticoid-induced Osteoporosis

Rheum Dis Clin North Am. 2016 Feb;42(1):177-89, x. doi: 10.1016/j.rdc.2015.08.005. Epub 2015 Oct 24.

Abstract

Glucocorticoid-induced osteoporosis (GIOP) is one of the most common and serious adverse effects associated with glucocorticoid use. This article highlights GIOP pathophysiology, epidemiologic associations, effective treatment, and lifestyle modifications that can reduce fracture risk for long-term glucocorticoid users and additionally emphasizes the importance of early intervention.

Keywords: Fracture risk; Glucocorticoids; Osteoporosis; Prevention.

Publication types

  • Review

MeSH terms

  • Bone Density
  • Bone Density Conservation Agents / therapeutic use*
  • Glucocorticoids / adverse effects*
  • Humans
  • Osteoporosis / chemically induced*
  • Osteoporosis / drug therapy
  • Osteoporosis / prevention & control
  • Osteoporotic Fractures / chemically induced*
  • Osteoporotic Fractures / prevention & control
  • Risk Assessment

Substances

  • Bone Density Conservation Agents
  • Glucocorticoids